skip to Main Content
Easl-press-release-VH

‘Real-world’ effectiveness of elbasvir/grazoprevir confirmed in people with hepatitis C virus infection who inject drugs and/or receive opioid substitution therapy

ILC 2019: ‘Real-world’ studies confirm the effectiveness of elbasvir/grazoprevir in people with hepatitis C (HCV) genotype 1 infection who inject and/or abuse drugs or who receive opioid substitution therapy 13 April 2019, Vienna, Austria EASL (EUROPEAN ASSOCIATION FOR THE STUDY…

Read More